Moclobemide
Severe
Textbook
Increased risk of adverse cardiovascular effects.
At least 2 weeks should elapse between the use of MAO inhibitors and administration of β2 agonists or other sympathomimetics.
Source: G&G 14e · p264
Drug reference
pirbuterol
β2-selective adrenergic receptor agonist · Bronchodilator
β2-selective adrenergic receptor agonistBronchodilatorATC R03AC05
CDSCO approvedATC R03AC05
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 12 →
- MoclobemideSevereTextbookG&G 14e · p264
- CarteololSevereDatabaseDDInter
- CarvedilolSevereDatabaseDDInter
- LabetalolSevereDatabaseDDInter
Mechanism
Pirbuterol is a relatively selective β2 adrenergic receptor agonist that causes relaxation of bronchial smooth muscle.
Indications
asthmaCOPD
Pharmacokinetics
Duration
~3-4 h
Side effects
Common
Muscle tremorTachycardiaPalpitations
Serious
- Hypokalemia
- Ventilation-perfusion (V/Q) mismatch (fall in arterial oxygen tension)
- Metabolic effects (increase in free fatty acid, insulin, glucose, pyruvate, and lactate)
Drug interactions
Carteolol
Severe
Database
Drug interaction classified as: antagonism
Source: DDInter
Carvedilol
Severe
Database
Drug interaction classified as: antagonism
Source: DDInter
Labetalol
Severe
Database
Clinical effect not specified
Source: DDInter
Levobunolol
Severe
Database
Clinical effect not specified
Source: DDInter
Macimorelin
Severe
Database
Clinical effect not specified
Source: DDInter
Metipranolol
Severe
Database
Clinical effect not specified
Source: DDInter
Nadolol
Severe
Database
Clinical effect not specified
Source: DDInter
Ozanimod
Severe
Database
Clinical effect not specified
Source: DDInter
Penbutolol
Severe
Database
Clinical effect not specified
Source: DDInter
Pindolol
Severe
Database
Clinical effect not specified
Source: DDInter
Propranolol
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Other β2-selective adrenergic receptor agonist drugs
Ask House about pirbuterol
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team